ASX 200 midday update: Brambles rockets, Goodman upgrades guidance

The ASX 200 is having a decent start to the week…

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

At lunch on Monday, the S&P/ASX 200 Index (ASX: XJO) has started the week on a reasonably positive note. The benchmark index is currently up 0.3% to 7,096.5 points.

Here's what is happening on the ASX 200 today:

Goodman Q3 update impresses

The Goodman Group (ASX: GMG) share price is pushing higher on Monday. This follows the release of the industrial property company's third quarter update. That update revealed that Goodman has continued its strong form during the period. So much so, it has upgraded its earnings per share growth guidance from 20% to 23% for FY 2022.

Brambles is a takeover target

The Brambles Limited (ASX: BXB) share price is racing higher today after the logistics solutions company confirmed that it is a takeover target. However, while it is in discussions with private equity giant CVC Partners, it hasn't received a proposal as of yet. At the rate that private equity firms are making deals, there'll be fewer and fewer quality blue chip options for Australian investors in the coming years.

Tech shares storm higher

A key driver of the ASX 200's gains on Monday has been the tech sector. Thanks to an explosive night of trade on the Nasdaq index on Friday, the S&P/ASX All Technology Index is up 2.5% today. Appen Ltd (ASX: APX) and Megaport Ltd (ASX: MP1) are among the best performers in the sector today.

Best and worst ASX 200 performers

The best performer on the ASX 200 on Monday has been the Brambles share price with a 10% gain. This follows new of its takeover talks with CVC. Going the other way, the Imugene Limited (ASX: IMU) share price is the worst performer with a 5.5% decline on no news. This leaves the biotech trading within a whisker of its 52-week low.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Appen Ltd and MEGAPORT FPO. The Motley Fool Australia has recommended MEGAPORT FPO. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man in a suit smiles at the yellow piggy bank he holds in his hand.
Share Market News

Forget Westpac shares, these ASX ETFs could be better buys

Here's why these funds could be quality picks for investors looking for alternatives to the banks.

Read more »

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.
Share Gainers

Here are the top 10 ASX 200 shares today

It was another tough day for investors.

Read more »

Rising real estate share price.
REITs

Macquarie names its top 4 ASX REITs to buy today

Macquarie expects these four dividend paying ASX REITs will all surge higher in 2026.

Read more »

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
Opinions

Forget CSL shares, I'd buy this booming biotech stock instead

This ASX biotech stock has caught my eye this year.

Read more »

Man with virtual white circles on his eye and AI written on top, symbolising artificial intelligence.
Broker Notes

Why this ASX AI stock could return 40% in 2026

Let's see which stock Bell Potter is tipping to rise strongly.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Telix Pharmaceuticals shares crash 58% from their peak: Buying opportunity or time to sell up?

The biopharmaceutical company's shares are tipped to soar next year.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Share Market News

Analysts name 2 top ASX 200 shares to buy today

Leading investment experts name two quality ASX 200 shares to buy now.

Read more »

Woman leaping in the air and standing out from her friends who are watching.
Broker Notes

This ASX 200 gold stock has surged 77% in 2025. Here's why Macquarie expects it to leap another 23%

Macquarie forecasts 23% upside for this surging ASX gold stock, and that doesn’t include the dividends!

Read more »